Praxis Investment Management Inc. Cuts Stake in Teleflex Incorporated $TFX

Praxis Investment Management Inc. decreased its holdings in Teleflex Incorporated (NYSE:TFX) by 30.0% in the second quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 1,750 shares of the medical technology company’s stock after selling 750 shares during the period. Praxis Investment Management Inc.’s holdings in Teleflex were worth $207,000 as of its most recent SEC filing.

A number of other institutional investors also recently made changes to their positions in the business. Thompson Investment Management Inc. boosted its stake in shares of Teleflex by 2.1% in the 2nd quarter. Thompson Investment Management Inc. now owns 4,970 shares of the medical technology company’s stock valued at $588,000 after purchasing an additional 100 shares in the last quarter. CX Institutional boosted its position in Teleflex by 14.7% during the 2nd quarter. CX Institutional now owns 872 shares of the medical technology company’s stock valued at $103,000 after buying an additional 112 shares during the period. Signaturefd LLC boosted its position in Teleflex by 38.3% during the 1st quarter. Signaturefd LLC now owns 433 shares of the medical technology company’s stock valued at $60,000 after buying an additional 120 shares during the period. Empirical Finance LLC boosted its position in Teleflex by 7.9% during the 1st quarter. Empirical Finance LLC now owns 1,690 shares of the medical technology company’s stock valued at $234,000 after buying an additional 124 shares during the period. Finally, Northwestern Mutual Wealth Management Co. boosted its position in Teleflex by 30.2% during the 1st quarter. Northwestern Mutual Wealth Management Co. now owns 556 shares of the medical technology company’s stock valued at $77,000 after buying an additional 129 shares during the period. Hedge funds and other institutional investors own 95.62% of the company’s stock.

Teleflex Stock Up 3.7%

Shares of NYSE TFX opened at $128.44 on Monday. The company has a current ratio of 2.41, a quick ratio of 1.44 and a debt-to-equity ratio of 0.42. Teleflex Incorporated has a 12 month low of $108.90 and a 12 month high of $241.41. The firm has a market capitalization of $5.68 billion, a PE ratio of 30.22, a price-to-earnings-growth ratio of 1.79 and a beta of 1.05. The firm has a fifty day simple moving average of $125.09 and a two-hundred day simple moving average of $123.52.

Teleflex (NYSE:TFX) last issued its quarterly earnings data on Thursday, July 31st. The medical technology company reported $3.73 EPS for the quarter, topping the consensus estimate of $3.36 by $0.37. Teleflex had a net margin of 6.31% and a return on equity of 15.08%. The business had revenue of $780.90 million during the quarter, compared to analyst estimates of $771.53 million. During the same period in the prior year, the business earned $3.42 EPS. The company’s revenue for the quarter was up 4.2% on a year-over-year basis. Teleflex has set its FY 2025 guidance at 13.900-14.300 EPS. Equities analysts expect that Teleflex Incorporated will post 13.98 earnings per share for the current year.

Teleflex Announces Dividend

The firm also recently declared a quarterly dividend, which was paid on Monday, September 15th. Investors of record on Friday, August 15th were paid a $0.34 dividend. This represents a $1.36 annualized dividend and a dividend yield of 1.1%. The ex-dividend date was Friday, August 15th. Teleflex’s dividend payout ratio (DPR) is presently 32.00%.

Analyst Upgrades and Downgrades

Several equities research analysts have weighed in on the stock. Zacks Research cut shares of Teleflex from a “strong-buy” rating to a “hold” rating in a research report on Tuesday, September 30th. Mizuho increased their price target on shares of Teleflex from $130.00 to $135.00 and gave the company a “neutral” rating in a research report on Friday, August 1st. Weiss Ratings reissued a “sell (d+)” rating on shares of Teleflex in a research report on Wednesday, October 8th. Royal Bank Of Canada increased their price target on shares of Teleflex from $130.00 to $135.00 and gave the company a “sector perform” rating in a research report on Friday, August 1st. Finally, Wall Street Zen lowered shares of Teleflex from a “strong-buy” rating to a “buy” rating in a report on Monday, September 15th. One equities research analyst has rated the stock with a Buy rating, nine have issued a Hold rating and two have assigned a Sell rating to the company’s stock. According to MarketBeat.com, the company has an average rating of “Reduce” and a consensus price target of $141.57.

Insider Buying and Selling

In other Teleflex news, CEO Liam Kelly purchased 1,500 shares of the firm’s stock in a transaction that occurred on Tuesday, August 5th. The stock was bought at an average cost of $115.07 per share, for a total transaction of $172,605.00. Following the purchase, the chief executive officer directly owned 45,267 shares in the company, valued at $5,208,873.69. The trade was a 3.43% increase in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director Stuart A. Randle purchased 1,000 shares of the firm’s stock in a transaction that occurred on Tuesday, August 5th. The stock was acquired at an average price of $115.86 per share, with a total value of $115,860.00. Following the completion of the purchase, the director owned 7,547 shares in the company, valued at $874,395.42. This represents a 15.27% increase in their ownership of the stock. The disclosure for this purchase can be found here. Insiders purchased 5,500 shares of company stock worth $633,590 over the last 90 days. Corporate insiders own 1.40% of the company’s stock.

Teleflex Profile

Teleflex Incorporated designs, develops, manufactures, and supplies single-use medical devices for common diagnostic and therapeutic procedures in critical care and surgical applications worldwide. The company provides vascular access products that comprise Arrow branded catheters, catheter navigation and tip positioning systems, and intraosseous access systems for the administration of intravenous therapies, the measurement of blood pressure, and the withdrawal of blood samples through a single puncture site.